Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Feng Zhang, Gregory A. Rippon, Sunfa Cheng, Daniel D. Mikol

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension'. Together they form a unique fingerprint.

Medicine & Life Sciences